Overview Studies

DAIsy

Major depressive disorder (MDD) is a common psychiatric disorder, ranking as the second leading contributor of years lived with disability. Finding the right approach for individual patients remains challenging. DAIsy will develop and bring to the market AI-supported solutions for improved diagnosis, treatment selection, monitoring with diet and activity tracking, support in behavior adjustments, and treatment response assessment. Novel AI techniques will jointly be developed to advance the AI applicability for these fragile patients by advancing techniques for large data points / patient ratios, improving explainability and uncertainty quantification.

Participation in this international research consortium on the diagnosis and treatment of depression is funded by the EU.
Further information about DAIsy can be found here.

AwareMe

The aim of the BMBF joint project AwareMe is to develop a modular and interactive medical technology that supports the self-management of behavioural disorders for young adults unobtrusively in everyday life. For example, body-worn medical technology for ADHD is being developed here. The symptoms relevant to the behavioural disorder are detected both in inconspicuous worn sensors and by smartphone-based experience sampling.

For more information on the AwareMe project, click here.

ESCAlate

As a sub-project of the BMBF-funded ESCAlife joint project, ESCAlate focuses on the treatment of ADHD in young adults. The concrete goal of ESCAlate is to investigate the effectiveness of an adaptive and gradual treatment program, which is based on three different treatment methods: Psychopharmaceutical therapy, neurofeedback training and psychoeducation.

Patients with ADHD are welcome to participate in an ongoing study.

More detailed information about the ESCAlate project can be found here.

PSYY-PGx

PSY-PGx is a research project aimed at the personalization of psychiatric pharmacotherapy and thereby enabling better treatment outcomes. PSY-PGx is a unique, non-commercial international initiative, carried by researchers and non-profit organizations. In first instance, psychiatric patients will be genotyped in a clinical study and their pharmacotherapy will be individualized based on their genetic characteristics. The data collected from this study will be used in the next step to develop an algorithm for personalized psychiatric pharmacotherapy. Data from European biobanks will also be used in this process. This should lead to a novel approach to genome-based, individualized psychiatric pharmacotherapy. This project is an international collaboration of clinics and research institutes worldwide, the international patient-advocacy network Global Alliance of Mental Illness Advocacy Network (GAMIAN) and the World Psychiatric Association (WPA).
For more information on the PSY-PGx project, click here.

PRECISE

This research project ist concerned with the validation of the clinical decision support system PGXperts. With the help of this medical product, pharmacogenetic characteristics of individual patients and interaction risk profile of psychiatric drugs are automatically provided to a treating physician. In molecular genetic studies by the Institute of Human Genetics at the University Hospital Bonn these data are automatically analyzed and used to draw conclusions about patients drug metabolism. This will enable physicians to prescribe medication that is personalized and optimized in terms of dosage, pharmacodynamics and -kinetics. Patients with a diagnosis of depression can participate in this study. The study is a joint project of HMG Systems Engineering GmbH, Fürth, the Clinic of Psychiatry and Psychotherapy, the Institute for Experimental and Clinical Pharmacology and the Institute for Medical Informatics and Statistics UKSH and the Human Genetics Institute and the Clinic of Psychiatry and Psychotherapy at the University Hospital Bonn.

ATTENTION

ADHD treatment in adults usually consists of an drug and/or psychotherapeutic treatment, whereby the drug treatment success is usually higher than the psychotherapeutic treatment success. However, drug ADHD treatment often leads to undesirable side effects and must also be closely monitored. The development of further, effective and low-side ADHD therapy approaches therefore appears to be urgently indicated. The aim of the BMBF-funded ATTENTION project is to develop a novel medical-technical system for targeted neuromodulation of attention-associated cortical networks through electrostimulation.
More detailed information about the ATTENTION project can be found here.

GENERATE

The mission of the GErman NEtwork for Research on AuToimmune Encephalitis (GENERATE) is to empower cooperation between centers with clinical and scientific expertise. GENERATE will enable us to better characterize the immunopathogenesis and neuropathophysiology of the different autoimmune encephalitides while elucidating the clinical particulars, clinical courses and treatment strategies.
For more information on GENERATE click here.

You can find opportunities for study participation here.

You can find the study participation pool here.

Collaborators in the field of Psychiatric Pharmacogenetics (Project PRECISE)

Institut für Humangenetik, Universitätsklinikum Bonn
HMG Systems Engnineering GmbH, Fürth
Institut für Medizinische Informatik und Statistik UKSH Kiel

Collaborators in the field of ADHD

Fraunhofer Institute for Digital Media Technology IDMT
OFFIS Institute for Computer Science, Interactive Systems at the University of Oldenburg
Prof. Dr. Herrmann, University of Oldenburg
As well as cooperation within the ESCAlate consortium

Collaborators in the field of Molecular and Clinical Psychotraumatology

Federal Ministry of Defence
University Medicine Göttingen Clinic for Psychiatry and Psychotherapy

Collaborators in the field of neurohomeostasis

Daniel Heinz, Guest Scientist (Max Planck Institute of Psychiatry, Munich)

Collaborators in the field of neuromodulation of emotions

Prof. Schramm University of Freiburg
Prof. Kumsta, University of Bochum
As well as cooperation within the ESPRIT project

Collaborators in the field of neurovegetative prediction research

University Witten-Herdecke
University Hospital Erlangen
University Hospital Oldenburg

Collaborators in the field of treatment of chronic depression, CBASP

Centre for Economics and Neuroscience Bonn
Prof. Dr. Dr. H. Walter, Charité Berlin
Mr. Priv. Doz. Dr. K. Schnell, Asklepios Specialist Hospital Göttingen
Prof. Dr. E. Schramm, Department of Psychiatry and Psychotherapy, University Hospital Freiburg
Prof. Dr. C. Normann, Department of Psychiatry and Psychotherapy, University Hospital Freiburg
Prof. Dr. H. Kessler, Department of Neuropsychology, Ruhr University Bochum
Prof. Dr. J. Krajewski, Institute for Experimental Psychophysiology, Düsseldorf

Collaborators in the field of virtual reality therapy and medical technology

Prof. Dr. Ulrich Ettinger, University of Bonn
Prof. Dr. C. Herrmann, University of Oldenburg
OFFIS Institute of the University of Oldenburg
Fraunhofer Institute for Digital Media Technology IDMT, Oldenburg
Prof. Reinhard Klein, University of Bonn

Collaborators in the field of obsessive-compulsive disorders

Dr. Sina Kohl, University Hospital Cologne
Dr. A. Ramirez, University Hospital Cologne, Clinic and Polyclinic for Psychiatry and Psychotherapy, Section Molecular Neuropsychiatry
Dr. Ralf Pukrop, University Hospital Cologne
Prof. Dr. Stephan Ruhrmann, University Hospital Cologne
Prof. Dr. Markus Nöthen, Institute for Human Genetics, University Hospital Bonn
Prof. Dr. Ulrich Ettinger, Rheinische Friedrich-Wilhelms-University Bonn
Prof. Dr. Matthias Schmid, Institute for Medical Biometry, Informatics and Epidemiology IMBIE, University of Bonn
Prof. Dr. Norbert Kathmann, Humboldt University of Berlin, Faculty of Life Sciences, Institute of Psychology
Prof. Dr. Stephan Heinzel, Free University Berlin
Prof. Dr. Hans Jörgen Grabe, Clinic for Psychiatry and Psychotherapy, University of Greifswald
Prof. Dr. Manuel Mattheisen, University Hospital Würzburg
Prof. Dr. Anja Riesel, University of Hamburg
Prof. Dr. Peter Falkai, Clinic for Psychiatry and Psychotherapy, University of Munich
Prof. Dr. Thomas G. Schulze, Institute for Psychiatric Phenomics and Genomics, University Hospital Munich

Collaborators in the field of Psychiatric Genomics and Pharmacogenetics (Project PSY-PGx):

Parnassia Groep BV (NL), Department of Psychiatry
Rijksuniversiteit Groningen (NL), Groningen Institute of Evolutionarey Life Science & Engineering (Behapp)
Farmaceutski Fakultet Univerzitetau Beogradu (RS), Faculty of Pharmacy
Universitatea Babes-Bolyai (RO), Department of Psychology
Helsinki University, Institute for Molecular Medicine Finland FIMM & Department of Public Health
Universiteit Maastricht (NL), Department of Psychiatry and Neuropsychology
Karolinska Institute (SE), Department of Physiology & Pharmacology
Tel Aviv University (IL), Sackler Faculty of Medicine
SUNY Upstate Medical University (US), Department of Psychiatry
King’s College London (UK), Institute of Psychiatry, Psychology & Neurosciences
Fundacio Clinic per la Recerca Biomedica (ES), Department of Psychiatry & Psychology
Global Alliance of Mental Illness Advocacy Networks Europe AISBL
World Psychiatric Association (CH)

Collaborators in the field of ADHD:

DAIsy project
TIMESPAN project
Donders Institute for Brain, Cognition and Behavior and the University of Groningen
University of Melbourne
Prof. Dr. Phil Asherton, King's College London
As well as cooperation within the ENIGMA consortium
And cooperation within the Psychiatric Genetic Consortium (PGC ADHD)

Collaborators in the field of Modulation of Stress and Resilience:

Computational Biology Research Group, Institute of Developmental Biology, Aix-Marseille University, France

Collaborators in the field of molecular and clinical psychotraumatology:

Maastricht University, Netherlands

Collaborators in the field of neurohomeostasis:

Dr. Dr. Jens Stepan, Guest Scientist, University Hospital Salzburg

Collaborators in the field of neurovegetative prediction research:

Klinikum Forchheim - Franconian Switzerland gGmb

Collaborators in the field of chronic depression therapy, CBASP:

Prof. Dr. JP McCullough, Virginia Commonwealth University, USA
Prof. JK Penberthy, University of Virginia, USA

Collaborators in the field of obsessive-compulsive disorders:

Prof. Dr. Dr. Jeremiah Scharf, Massachusetts General Hospital
Prof. Dr. Andreas Papassotiropoulos, Institute for Molecular Psychology, University of Basel
Prof. Dr. Carol Mathews, University of Southern California
Prof. Dr. Jonathan Mill, University of Exeter Medical School, UK
Dr Katie Lunnon, University of Exeter Medical School, UK
Dr Daniel van den Hove, Maastricht University
Prof. Dr. Antonio Del Sol, Luxembourg Centre for Systems Biomedicine (LCSB), Luxembourg